Intranasal administration of nanovectorized docosahexaenoic acid (dha) improves cognitive function in two complementary mouse models of alzheimer’s disease

HIGHLIGHTS

• who: Charleine Zussy and collaborators from the MMDN, University Montpellier, EPHE, INSERM, Montpellier, France have published the research: Intranasal Administration of Nanovectorized Docosahexaenoic Acid (DHA) Improves Cognitive Function in Two Complementary Mouse Models of Alzheimeru2019s Disease, in the Journal: Antioxidants 2022, 838 of 22/09/2010
• what: The authors show for the first time that the intranasal administration of nanovectorized reduces phosphorylation and restores cognitive functions in two complementary murine models of AD. In this model the authors further thought to determine whether increased Tau phosphorylation may result from an increased activation of the GSK3 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.